title: Effect of imexon treatment on Friend virus complex infection using genetically defined mice as a model for HIV-1 infection.
abstract: Imexon (4-imino-1,4-diazobicyclo-3.1.0-hexan-2-one) was moderately effective in the treatment of a retroviral infection in a genetically defined murine model. The animal model consisted of a Friend virus complex (FV) infection in a hybrid mouse strain, (B10.A x A/WySn)F1, which has similarities with acquired immune deficiency syndrome (AIDS). Intraperitoneal imexon initiated 1 or 3 days after FV inoculation and continued through 13 days after inoculation significantly reduced splenomegaly, splenic cell-free virus titers and viral RNA. Viral infectious centers/10(6) splenocytes and FV titers in the plasma were reduced, though not to a statistically significant level. The effect of imexon on survival was not statistically significant which suggested that the antiviral effects were only transiently effective. Phytohemagglutinin-induced blastogenesis and percent of total T cells, T helper cells and T suppressor/cytotoxic cells in the spleens were increased, and the percentage of B cells decreased by imexon treatment of both FV-infected and uninfected mice. The splenic natural killer cell activity and interleukin-1 production were not markedly affected. Virus specific neutralizing antibody developed in both imexon- and placebo-treated FV-infected mice, although titers were lower in the imexon-treated animals.
authors.affiliation: AIDS Research Program, Utah State University, Logan 84322-5600.
authors.forename: J D
authors.initials: JD
authors.lastname: Morrey
authors.forename: R P
authors.initials: RP
authors.lastname: Warren
authors.forename: K M
authors.initials: KM
authors.lastname: Okleberry
authors.forename: R A
authors.initials: RA
authors.lastname: Burger
authors.forename: M A
authors.initials: MA
authors.lastname: Chirigos
authors.forename: R W
authors.initials: RW
authors.lastname: Sidwell
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D000998:Antiviral Agents / Q000494:pharmacology*; D002452:Cell Count; D005260:Female; D005622:Friend murine leukemia virus / Q000187:drug effects* / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006588:Hexanones / Q000494:pharmacology*; D007942:Leukemia, Experimental / Q000188:drug therapy* / Q000382:microbiology; D008214:Lymphocytes / Q000187:drug effects / Q000382:microbiology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D008957:Models, Genetic; D010835:Phytohemagglutinins / Q000494:pharmacology; D012367:RNA, Viral / Q000032:analysis; D013163:Splenomegaly / Q000188:drug therapy / Q000382:microbiology
chemical_list: D000970:Antineoplastic Agents; D000998:Antiviral Agents; D006588:Hexanones; D010835:Phytohemagglutinins; D012367:RNA, Viral; C014919:4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one